Pharmaceutics (Sep 2021)

Melatonin Improves Levels of Zn and Cu in the Muscle of Diabetic Obese Rats

  • Miguel Navarro-Alarcón,
  • Fernando Gil-Hernández,
  • Cristina Sánchez-González,
  • Juan Llopis,
  • Marina Villalón-Mir,
  • Pablo Olmedo,
  • Pablo Alarcón-Guijo,
  • Diego Salagre,
  • Lorena Gaona,
  • Mario Paredes,
  • Ahmad Agil

DOI
https://doi.org/10.3390/pharmaceutics13101535
Journal volume & issue
Vol. 13, no. 10
p. 1535

Abstract

Read online

Melatonin improves metabolic alterations associated with obesity and its diabetes (diabesity). We intend to determine whether this improvement is exerted by changing Zn and/or Cu tissue levels in liver, muscle, pancreas, and brain, and in internal (perirenal, perigonadal, and omentum) and subcutaneous lumbar white adipose tissues (IWAT and SWAT, respectively). Male Zücker diabetic fatty (ZDF) rats and lean littermates (ZL) were orally supplemented either with melatonin (10 mg/kg body weight/day) or vehicle for 6 weeks. Zn and Cu concentrations were not significantly influenced by diabesity in the analyzed tissues (p > 0.05), with the exception of Zn in liver. In skeletal muscle Zn and Cu, and in perirenal WAT, only Zn levels increased significantly with melatonin supplementation in ZDF rats (p < 0.05). This cytoplasmic Zn enhancement would be probably associated with the upregulation of several Zn influx membrane transporters (Zips) and could explain the amelioration in the glycaemia and insulinaemia by upregulating the Akt and downregulating the inhibitor PTP1B, in obese and diabetic conditions. Enhanced Zn and Cu levels in muscle cells could be related to the reported antioxidant melatonin activity exerted by increasing the Zn, Cu-SOD, and extracellular Cu-SOD activity. In conclusion, melatonin, by increasing the muscle levels of Zn and Cu, joined with our previously reported findings improves glycaemia, insulinaemia, and oxidative stress in this diabesity animal model.

Keywords